Table 5 Potential directly and indirectly available activators of the LKB1-AMPK pathway.
From: Immunometabolism in cancer: basic mechanisms and new targeting strategy
Target | Drug | Phase/status | Tumor type | Treatment | ClinicalTrials. govIdentifier |
|---|---|---|---|---|---|
LKB1-AMPK activators | |||||
AMPK | Metformin | III Ongoing | Endometrial cancer stage I | Monotherapy | |
II Ongoing | Metastatic prostate cancer | Monotherapy | |||
II Ongoing | Bladder cancer | Monotherapy | |||
IV Ongoing | Breast cancer female | With Atorvastatin | |||
Early I Ongoing | Prostate cancer | Monotherapy | |||
III Ongoing | Non-small cell lung cancer | Monotherapy | |||
I Ongoing | Advanced pancreatic cancer, advanced solid tumor | With Simvastatin, Digoxin | |||
II Ongoing | Hepatocellular cancer, pancreatic cancer, gastric cancer, colorectal cancer | With Vitamin C | |||
II Ongoing | Head and neck squamous cell carcinoma | With Pembrolizumab | |||
I Ongoing | Oral cavity carcinoma | Monotherapy | |||
II Ongoing | Preleukemia | Monotherapy | |||
II Ongoing | Osteosarcoma Ewing sarcoma | Monotherapy | |||
II Ongoing | Glioblastoma | With Temozolomide | |||
I/II Ongoing | Melanoma | With Vemurafenib | |||
I/II Ongoing | Melanoma | With Dabrafenib, Trametinib | |||
II Ongoing | Relapsed chronic lymphocytic leukemia | Monotherapy | |||
II Completed | Breast cancer | Monotherapy | |||
II Completed | Prostate cancer | Monotherapy | |||
II Completed | Colon cancer | Monotherapy | |||
I Completed | Epithelial ovarian cancer | With Carboplatin, Paclitaxel | |||
II Completed | Locally advanced pancreatic cancer Metastatic pancreatic cancer | With gemcitabine, erlotinib | |||
Resveratrol | I Completed | Colon cancer | Monotherapy | ||
I Completed | Adenocarcinoma of the colon, Adenocarcinoma of the rectum | Monotherapy | |||
Alpha lipoic acid | I Ongoing | Head and neck squamous cell carcinoma | Monotherapy | ||
